Sirolimus
- TRADE NAMES: Rapamune (Wyeth); Rapamycin
- INDICATIONS: Prophylaxis of organ rejection in renal transplants, lymphangioleiomyomatosis
- SYNONYM: rapamycin
- CLASS: Immunosuppressant, Macrolactam, Non-calcineurin inhibitor
- HALF-LIFE: 62 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Atazanavir, Benazepril, Boceprevir, Captopril, Ceritinib, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Crizotinib, Cyclosporine, Darunavir, Dasatinib, Delavirdine, Dronedarone, Efavirenz, Eluxadoline, Enalapril, Enzalutamide, Fosinopril, Hemophilus B Vaccine, Indinavir, Itraconazole, Letermovir, Lisinopril, Lopinavir, Micafungin, Mifepristone, Posaconazole, Quinapril, Ramipril, Ribociclib, St John's Wort, Tacrolimus, Telaprevir, Telithromycin, Tipranavir, Venetoclax, Viloxazine, Voriconazole, Zotarolimus
PREGNANCY CATEGORY: C
IMMUNOSUPPRESSION, USE IS NOT RECOMMENDED IN LIVER OR LUNG TRANSPLANT PATIENTS
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
HAIR.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTIC.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 01/20/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
